Arcellx to Present at Jefferies Virtual Cell Therapy Summit
GAITHERSBURG, Md., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Arcellx today announced that David Hilbert, Chief Executive Officer, will present at the following upcoming investor conference.
Presentation Details:
Event: Jefferies Virtual Cell Therapy Summit
Date: Monday, Oct. 5, 2020
Time: 4:30 p.m. ET
To view the live presentation, click here:
https://wsw.com/webcast/jeff146/arce/1823250
About Arcellx’s ARC-sparX Platform Technology
The ARC-sparX platform separates the tumor-recognition and tumor-killing functions of conventional CAR-T cell therapies: (1) sparX (soluble protein antigen-receptor X-linkers) proteins recognize and bind specific antigens on diseased cells and flag those cells for destruction; and (2) ARC-T (Antigen Receptor Complex-T) cells bind the sparX proteins and kill the flagged cells. Arcellx has developed a collection of sparX proteins that bind different cell surface antigens. Administration of alternate sparX proteins can redirect ARC-T cells to different disease antigens to potentially address relapsed and refractory disease due to tumor heterogeneity or antigen escape. Additionally, ARC-T cell activity can be curbed as needed by controlling the dose and frequency of sparX administration.
About Arcellx, Inc.
Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. More information can be found at www.arcellx.com.
Contact:
Investors
Solebury Trout
Alan Lada
Tel: 646-378-2927
Email: alada@soleburytrout.com
Media
Solebury Trout
Zara Lockshin
Tel: 646-378-2960
Email: zlockshin@soleburytrout.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
